Details of the Drug Combination

General Information of Drug Combination (ID: DC8DT7B)

Drug Combination Name
Pertuzumab Trastuzumab
Indication
Disease Entry Status REF
Breast cancer Phase 1 [1]
Component Drugs Pertuzumab   DMHJV0X Trastuzumab   DMZQOUX
Monoclonal antibody Antibody

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pertuzumab
Disease Entry ICD 11 Status REF
Adrenal gland neoplasm N.A. Approved [2]
Breast cancer 2C60-2C65 Approved [3]
Neuroblastoma 2D11.2 Investigative [2]
Pertuzumab Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Indication(s) of Trastuzumab
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [4]
Inflammatory breast cancer 2C62 Approved [5]
Lung cancer 2C25.0 Approved [6]
Gastric adenocarcinoma 2B72 Application submitted [1]
HER2-positive breast cancer 2C60-2C65 Application submitted [1]
Gastric cancer 2B72 Investigative [7]
Trastuzumab Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN . [9]
------------------------------------------------------------------------------------
Trastuzumab Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases ADR [10]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082).
5 Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32.
6 Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251.
7 The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 Dec;600(7890):727-730.
8 Clinical pipeline report, company report or official report of Roche (2009).
9 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.